Q00987 (MDM2_HUMAN) Homo sapiens (Human)

E3 ubiquitin-protein ligase Mdm2 UniProtKBInterProSTRINGInteractive Modelling

491 aa; Sequence (Fasta) ; (Isoform 2; Isoform 3; Isoform 4; Isoform 5; Isoform 6; Isoform 7; Isoform 8; Isoform 9; Isoform 10; Isoform 11)

Available Structures

142 Experimental Structures

DescriptionPDB IDOligo-stateRangeSeq id (%)Ligands
Structure of complex of MDM2(3-109) and P73 TAD(10-25) Heteromer
O15350;
3-109
100
Green fluorescent protein linked MTide-02 inhibitor in complex with mdm2 Heteromer
15-110
100GOL;PO4;PG4;
Structure of the MDM2 P53 binding domain in complex with H103, an all-D Helicon Polypeptide, altern… Heteromer
17-111
100EDO;SO4;DMS;WHL;
MDM2 bound CueO-PM2 sensor Heteromer
P36649;
25-111
100
Structure of the MDM2 P53 binding domain in complex with H101, an all-D Helicon Polypeptide Heteromer
25-110
100CL;WHL;
Crystal structure of beta-catenin and the MDM2 p53-binding domain in complex with H330, a Helicon P… Heteromer
P35222;
25-110
100WHL;
Crystal structure of the computationally designed chemically disruptable heterodimer LD6-MDM2 Heteromer
Q328D2;
25-110
100
Crystal structure of beta-catenin and the MDM2 p53-binding domain in complex with H329, a Helicon P… Heteromer
P35222;
25-110
100WHL;
Crystal structure of beta-catenin and the MDM2 p53-binding domain in complex with H332, a Helicon P… Heteromer
P35222;
25-110
100WHL;
Crystal structure of p53 epitope-scaffold based on a inhibitor of cysteine proteases in complex wit… Heteromer
26-110
100CL;SO4;GOL;
MDM2 BOUND TO THE TRANSACTIVATION DOMAIN OF P53 Heteromer
P04637;
25-109
100
Crystal structure of beta-catenin and the MDM2 p53-binding domain in complex with H333, a Helicon P… Heteromer
P35222;
26-110
100WHL;
Crystal structure of human MDM2 in complex with a potent miniature protein inhibitor (18-residues) Heteromer
27-109
100ACT;CL;
Crystal Structure of an MDM2/P53 Peptide Complex Heteromer
P04637;
26-108
97.59SO4;
Solution structure of Hdm2 with engineered cyclotide Heteromer
27-109
100
Crystal Structure of the MDM2-MDMX RING Domain Heterodimer Heteromer
O15151;
428-491
100ZN;
Structure of MDM2-MDMX-UbcH5B-ubiquitin complex Heteromer
O15151; P0CG47; P62837;
429-491
100ZN;SO4;
Crystal structure of human MDM2 RING domain homodimer bound to UbcH5B-Ub Heteromer
P62837; P62979;
430-491
100ZN;CL;NO3;
Crystal structure of human MDM2-G443T RING domain homodimer bound to UbcH5B-Ub (Crystal form 1) Heteromer
P0CG47; P62837;
430-491
98.39CL;ZN;EDO;
Crystal structure of human MDM2-G443T RING domain homodimer bound to UbcH5B-Ub (Crystal form 2) Heteromer
P0CG47; P62837;
430-491
98.39CL;ZN;EDO;
Crystal Structure of the MDM2-MDMX RING Domain Heterodimer Heteromer
O15151;
432-491
100ZN;
Crystal structure of human MDM2-RPL11 Heteromer
P62913;
293-334
100IMD;BME;ZN;
human MDM2-5S RNP Heteromer
P46777; P62913;
293-334
100ZN;
Human 14-3-3 sigma in complex with human MDM2 peptide Heteromer
P31947;
164-187
100.0GOL;PEG;CL;MG;
Crystal Structure of the USP7:Hdm2(PSTS) complex Heteromer
Q93009;
395-401
100
14-3-3 sigma in complex with hDM2-186 peptide Heteromer
P31947;
183-188
100IOD;
The Crystal Structure of the N-terminal domain of HAUSP/USP7 complexed with mdm2 peptide 147-150 Heteromer
Q93009;
145-150
100
CRYSTAL STRUCTURE OF HUMAN MDM2 WITH AN IMIDAZOLINE INHIBITORhomo-3-mer25-109
98.82IMZ;
Structure of MDM2 with low molecular weight inhibitor with aliphatic linker.homo-2-mer11-111
1006GG;
Structure of Human MDM2 in complex with a Benzodiazepine Inhibitorhomo-2-mer16-111
98.96DIZ;
Structure of a stapled peptide antagonist bound to Nutlin-resistant Mdm2.homo-2-mer18-112
98.95
Structure of MDM2 with low molecular weight inhibitor with aliphatic linker.homo-2-mer18-111
1006GG;
Inhibitor of MDM2-p53 Interactionhomo-2-mer17-110
98.92TVH;
X-ray structure of the p53-MDM2 inhibitor NMI801 bound to HDM2 at 2.1A resolutionhomo-2-mer19-111
100H0W;
Structure of hMDM2 in complex with Nutlin-3a-aahomo-2-mer25-111
100BME;M0L;
Crystal structure of human MDM2 with a 12-mer peptide inhibitor PMI (N8A mutant)homo-2-mer25-109
100CL;
Structure of hDM2 with Dimer Inducing Indolyl Hydantoin RO-2443homo-2-mer25-109
98.8103M;
Crystal structure of human MDM2 in complex with a 12-mer peptide inhibitorhomo-2-mer26-109
100GAI;
Crystal structure of human MDM2 in complex with D-peptide inhibitor (DPMI-alpha)homo-2-mer26-108
100SO4;CL;
Solution Structure of Hdm2 RING Finger Domainhomo-2-mer429-491
100ZN;
NMR Structure of Mdm2 (6-125) with Pip-1monomer1-125
10013Q;
NMR structure of unliganded MDM2monomer1-118
100
Ordering of the N Terminus of Human MDM2 by Small Molecule Inhibitorsmonomer6-111
1000Y7;
Co-crystal Structure of MDM2 in Complex with AM-7209monomer6-110
1003UD;SO4;
Co-Crystal Structure of MDM2 with Inhibitor Compound 4monomer6-110
1002U0;SO4;
MDM2 in complex with SAR405838monomer10-111
100.07HC;SO4;GOL;
Co-Crystal Structure of MDM2 with Inhbitor Compound 3monomer11-110
1002U5;SO4;
Co-Crystal Structure of MDM2 with Inhbitor Compound 46monomer12-110
1002U6;SO4;
Co-Crystal Structure of MDM2 with Inhibitor Compound 47monomer12-110
1002U1;
Chemical Shift Assignments for MIP and MDM2 in bound statemonomer6-102
100
Structure of the stapled peptide YS-01 bound to MDM2monomer17-112
97.92
Structure of the stapled peptide YS-02 bound to MDM2monomer17-112
97.92
HDM2 in complex with a 3,3-Disubstituted Piperidinemonomer18-113
97.9262T;SO4;
Structure of MDM2 with low molecular weight inhibitormonomer18-113
100B5K;
Human MDM2 liganded with a 12mer peptide inhibitor (pDI6W)monomer17-112
100
Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-bas…monomer17-111
1006ZT;SO4;CL;
Structure-activity studies of Mdm2/Mdm4-binding stapled peptides comprising non-natural amino acidsmonomer18-112
98.95
HDM2 in complex with compound 63monomer17-111
1001I9;GOL;CL;
HDM2 in complex with compound 56monomer17-111
1001I0;
Structure of the MDM2 P53 binding domain in complex with H103, an all-D Helicon Polypeptidemonomer17-111
100SO4;CL;WHL;
Structure of Mdm2 with low molecular weight inhibitormonomer18-112
1004NJ;
HDM2 in complex with compound 62monomer17-111
1001I3;SO4;
Discovery of New Natural-product-inspired Spiro-oxindole Compounds as Orally Active Inhibitors of t…monomer17-111
100GOL;SO4;6SS;
HDM2 (17-111, WILDTYPE) COMPLEXED WITH COMPOUND 9 AT 1.13A; Structural states of Hdm2 and HdmX: X-r…monomer18-111
100HTZ;CL;
HDM2 (17-111, WILDTYPE) COMPLEXED WITH COMPOUND 10 AT 1.21A; Structural states of Hdm2 and HdmX: X-…monomer17-110
100HU8;
Novel Spiro[3H-indole-3,2 -pyrrolidin]-2(1H)-one Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2…monomer18-111
1006SJ;SO4;
Novel Spiro[3H-indole-3,2 -pyrrolidin]-2(1H)-one Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2…monomer18-111
1006ST;ZN;SO4;
Crystal structure of MDM2 in complex with compound 13.monomer18-111
100H28;GOL;SO4;
In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitormonomer18-111
100EYH;CL;
Crystal structure of MDM2 with Brigimadlinmonomer17-109
100G7I;
HDM2 (17-111, WILD TYPE) COMPLEXED WITH NVP-HDM201 AT 1.56Amonomer19-111
1009QW;CL;
Structure of human MDM2 protein in complex with Mi-63-analogmonomer18-110
100MI6;
Exhaustive Fluorine Scanning towards Potent p53-MDM2 Antagonistmonomer18-110
10007G;
co-crystal structure of MDM2 (17-111) in complex with compound 25monomer18-110
1002SW;
co-crystal structure of MDM2 (17-111) with compound 16, {(3R,5R,6S)-5-(3-CHLOROPHENYL)-6-(4-CHLOROP…monomer18-110
100.035S;
Co-crystal structure of MDM2 with inhibitor (2'S,3R,4'S,5'R)-N-(2-aminoethyl)-6-chloro-4'-(3-chloro…monomer18-110
100.01MT;
Novel Spiro[3H-indole-3,2 -pyrrolidin]-2(1H)-one Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2…monomer19-111
1006SK;SO4;
HDM2 in complex with a 3,3-Disubstituted Piperidinemonomer21-113
97.8562R;SO4;
co-crystal structure of MDM2(17-111) in complex with compound 48monomer18-110
1002TZ;
Discovery of NVP-CGM097 - a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical …monomer18-110
1004T4;CL;
The Central Valine Concept Provides an Entry in a New Class of Non Peptide Inhibitors of the P53-MD…monomer18-110
98.92BLF;
Structure of a novel submicromolar MDM2 inhibitormonomer18-110
100Y30;SO4;
Structure of Mdm2 with low molecular weight inhibitor.monomer18-110
1004NX;
crystal structure of MDM2 with chromenotriazolopyrimidine 1monomer18-110
100YIN;
Co-Crystal Structure of MDM2 with Inhibitor Compound 49monomer18-110
100.02U7;
Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interactionmonomer18-110
98.922V8;
Co-crystal structure of MDM2 with inhibitor (2R,3E)-2-[(2S,3R,6S)-2,3-bis(4-chlorophenyl)-6-(4-fluo…monomer18-110
100.01MQ;
Crystal Structure of HDM2 in complex with Nutlin-3amonomer20-111
100NUT;SO4;CL;IOD;
HDM2 in complex with a beta-hairpinmonomer23-114
100SO4;MPO;
Inhibitor of MDM2-p53 Interactionmonomer17-108
97.83DMS;EDO;SO4;TVK;
Co-crystal structure of MDM2 with Inhibitor Compound 4monomer19-110
100.02TW;
Structure of a stapled peptide bound to MDM2monomer17-108
97.83O9E;
Inhibitor of MDM2-p53 Interactionmonomer17-108
97.83DMS;EDO;SO4;TUW;
crystal structure of compound 16 bound to MDM2(17-111), {(3R,5R,6S)-5-(3-CHLOROPHENYL)-6-(4-CHLOROP…monomer19-110
10035T;
Inhibitor of MDM2-p53 Interactionmonomer17-108
97.83EDO;U3Z;
crystal structure of MDM2 (17-111) in complex with compound 29 (AM-8553)monomer19-110
1000R3;
HDM2 (17-111, WILD TYPE) COMPLEXED WITH COMPOUND 11 AT 2.0A; Structural states of Hdm2 and HdmX: X-…monomer19-110
100HRH;
Inhibitor of MDM2-p53 Interactionmonomer17-108
97.83SO4;TUZ;
Inhibitor of MDM2-p53 Interactionmonomer17-108
97.83SO4;TV5;
Co-crystal structure of MDM2 with inhibitor {(2S,5R,6S)-6-(3-chlorophenyl)-5-(4-chlorophenyl)-4-[(2…monomer19-110
100.01MY;
Crystal Structure of HDM2 in complex with Caylin-1monomer20-110
100CL;NA;SO4;AU0;DMS;
Crystal Structure of an MDM2/Nutlin-3a complexmonomer18-108
97.8NUT;SO4;
Discovery of NVP-CGM097 - a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical …monomer20-110
100.04TH;CL;
Crystal structure of Mdm2 bound to a stapled peptidemonomer18-108
97.8FL5;
crystal structure of MDM2 (17-111) in complex with compound 23monomer22-111
100.00R2;SO4;
X-ray structure of Mdm2 with modified p53 peptidemonomer24-113
100
Structure of a novel submicromolar MDM2 inhibitormonomer21-110
100TJ2;K;
HDM2 in complex with compound 2monomer24-112
97.751GI;SO4;CIT;
Crystal structure of HIS6-tagged Mdm2 with nutlin-3amonomer24-111
100NUT;
MDM2 in complex with an 8-mer p53 peptide analoguemonomer25-112
100
Structure of human MDM2 in complex with an optimized p53 peptidemonomer23-110
100SO4;
The 1.25A Crystal structure of His6-tagged Mdm2 in complex with nutlin-3amonomer24-110
100NUT;
Structure of the MDM2 P53 binding domain in complex with H102, an all-D Helicon Polypeptidemonomer25-111
100EDO;CL;GOL;WHL;IMD;
MDM2 bound with a peptoidmonomer25-111
100UAC;CL;
Crystal structure of hDM2 in complex with a C-terminal triurea capped peptide chimera foldamer.monomer25-111
98.85
HDM2 (17-111, WILD TYPE) COMPLEXED WITH COMPOUND 12 AT 1.8A; Structural states of Hdm2 and HdmX: X-…monomer25-111
100HRE;SO4;
Structure of human MDM2 in complex with high affinity peptidemonomer25-111
100
Structure of the Stapled p53 Peptide Bound to Mdm2monomer24-110
100CL;
X-RAY STRUCTURE OF HDM2/CMR19 AT 1.45A: Discovery, X-ray structure and CPP-conjugation enabled upta…monomer26-111
100SO4;
Mdm2 in complex with a D amino Acid Containing Stapled Peptidemonomer26-111
100
Structure of a novel submicromolar MDM2 inhibitormonomer25-110
10028W;
HDM2 in complex with a 3,3-Disubstituted Piperidinemonomer26-111
97.6762Q;
CRYSTAL STRUCTURE OF HUMAN MDM2 IN COMPLEX WITH D-PEPTIDE INHIBITOR (DPMI-OMEGA)monomer25-109
100PEG;IPA;CL;
MDM2 bound to inhibitormonomer25-109
100
Macrocyclization of an all-D linear peptide improves target affinity and imparts cellular activity:…monomer25-109
100
Crystal structure of human MDM2 in complex with a 12-mer lysine-cysteine side chain dithiocarbamate…monomer25-109
100
Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Pro…monomer25-109
98.82EPE;DMS;M9E;
Crystal structure of human mdm2 with a dihydroimidazothiazole inhibitormonomer25-109
98.82LTZ;SO4;
Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Pro…monomer25-109
98.82M9H;
Co-crystal structure of MDM2 with inhibitor (2S,5R,6S)-2-benzyl-5,6-bis(4-bromophenyl)-4-methylmorp…monomer26-110
1001MN;SO4;
Structure of human MDM2 protein in complex with a small molecule inhibitormonomer26-110
98.82K23;SO4;
Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Pro…monomer25-109
98.82
Co-crystal structure of MDM2 with inhibitor (2S,5R,6S)-2-benzyl-5,6-bis(4-chlorophenyl)-4-methylmor…monomer26-110
1001MO;SO4;
Crystal structure of human mdm2 with a dihydroimidazothiazole inhibitormonomer25-109
98.82VZV;
Crystal structure of human MDM2 in complex with a trifluoromethylated D-peptide inhibitormonomer26-109
100SO4;
Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with…monomer25-108
98.814SS;
Human MDM2 liganded with a 12mer peptide inhibitor (pDIQ)monomer26-108
100EDO;
Structure of the Stapled Peptide Bound to Mdm2monomer26-108
97.59P07;
CRYSTAL STRUCTURE OF HUMAN MDM2 IN COMPLEX WITH 12-MER PEPTIDE INHIBITOR M3monomer27-108
100
Crystal structure of human MDM2 complexed with D-peptide (12 residues)monomer26-107
100
Solution structure of the C4 zinc-finger domain of HDM2monomer290-335
100ZN;
Solution structure of the C4 zinc-finger domain of HDM2monomer290-335
100ZN;

2 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
5j7f.2.Ahomo-2-mer0.8111-114
6GG;100.00
7ahz.1.Ahomo-2-mer0.76436-490
ZN;85.29

18 SWISS-MODEL models built on isoform sequence

IsoformTemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 26sqp.1.Bmonomer0.68229-296
ZN;91.18
Isoform 36sqp.1.Bmonomer0.70203-270
ZN;91.18
Isoform 34xxb.1.Bmonomer0.5377-113
ZN;97.78
Isoform 47ahy.1.Ahomo-2-mer0.76161-217
ZN;85.29
Isoform 44xxb.1.Bmonomer0.5222-61
ZN;96.38
Isoform 57bj0.1.Amonomer0.7717-58
85.71
Isoform 56sqp.1.Bmonomer0.66254-321
ZN;91.18
Isoform 65mnj.1.Cmonomer0.6770-132
ZN;100.00
Isoform 75j7f.2.Ahomo-2-mer0.7411-93
84.95
Isoform 87ahz.1.Ahomo-2-mer0.75375-429
ZN;85.29
Isoform 81ttv.1.Amonomer0.621-56
73.21
Isoform 97ah2.1.Amonomer0.71389-445
ZN;79.31
Isoform 95j7f.2.Amonomer0.5212-69
100.00
Isoform 105j7f.2.Ahomo-2-mer0.8111-114
6GG;100.00
Isoform 107ahz.1.Ahomo-2-mer0.77381-435
ZN;85.29
Isoform 115j7f.2.Ahomo-2-mer0.8117-120
6GG;100.00
Isoform 117ahz.1.Ahomo-2-mer0.75442-496
ZN;85.29
Isoform 114xxb.1.Bmonomer0.56299-340
ZN;100.00